RYSE Asset Management
VC Fund
London, United Kingdom
RYSE Asset Management is a VC fund in London focused on Health Care and Software. Our focus is to help healthcare founders go further. Since 2015, RYSE has been supporting technology companies to achieve accelerated global growth and scale by connecting high-potential healthcare founders with established distribution partners.In 2018/20, RYSE DigitalHealth.London investment programmes translated great ideas intoreal-world solutions by partnering with healthcare founders with clinical experience who know how to serve patients best.Our dream is to be globally admired as the most transformative partner for healthcare innovators.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries RYSE Asset Management invests in
Stages RYSE Asset Management invests in
Countries RYSE Asset Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Shabir Chowdhary
|
|||
Vivien de Tusch-Lec
|
|||
Chris Turner
|
|||
Dr John Lee Allen
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 11 (69%)
- Software 6 (38%)
- Medical 4 (25%)
- Apps 3 (19%)
- Information Technology 3 (19%)
Stage
- Funding Round 6 (38%)
- Venture - Series Unknown 5 (31%)
- Non-equity Assistance 2 (13%)
- Seed 1 (6%)
- Pre-Seed 1 (6%)
Country
- United Kingdom 9 (56%)
- United States 3 (19%)
- Spain 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Shabir Chowdhary
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
|
Vivien de Tusch-Lec
General Partner
|
General Partner | Total investments: 1 | Find email | |
|
Chris Turner
Entrepreneur-in-Residence
|
Entrepreneur-in-Residence | Total investments: 0 | Find email | |
Dr Carina Tyrrell
Entrepreneur-in-Residence
|
Entrepreneur-in-Residence | Total investments: 0 | Find email | |
|
Dr John Lee Allen
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ten63 Therapeutics
|
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | Venture - Series Unknown / Feb 19, 2026 | |
Curio
|
Curio is a developer of reliable technology and an analytics engine intended for the management of women's health. The corporate platform intends to provide individualized, research-based care for a range of problems affecting women's health, enabling consumers' behavioral and physical healthcare demands through the development oftailored therapies. It is dedicated to giving women of various ages and physiological problems contextualized care. | Venture - Series Unknown / Aug 28, 2024 | |
Braingaze
|
Braingaze solves major challenges around cognitive disorders of the brain. We use a patented neuro-biomarker based on small involuntary eye movements. These are triggered by functional games, the resulting signal is analysed using algorithms trained by Deep Learning based on actual real patient / control cases. We adress pre-symptomatic stagesof Alzheimer's disease and the most common child cognitive disorder ADHD. Our tools are on the market and covered by a CE Mark as a medical device. Our pipeline includes detection / diagnostic tools as well as digital therapy solutions that have shown to reduce symtoms by over 50%. | $1.6M / Venture - Series Unknown / Mar 06, 2024 | |
Vigilent Labs
|
Vigilent provides next-generation solutions to significantly enhance your defense, security and public safety capabilities. | Venture - Series Unknown / Oct 27, 2021 | |
Healthera
|
Healthera operates a leading healthcare marketplace that provides patients with medicines, healthcare services and products through the largest digital platform of pharmacies and GPs in the UK, including national chains and independent providers. Our technology empowers patients to access faster medicine delivery and personalised medical carelocal to them. We reinvent the pharmacy’s operating model which leads to better patient communication, more cross-sales and stronger customer loyalty.We focus on digitising and automating primary care processes in order to improve prescribing efficiency and patient experience while reducing wastage for the NHS. In partnership with over 1000 pharmacies and CCGs across the UK, Healthera has a reach of over 20 million. Our technology is accredited by NHS Digital and we are one of the fastest-growing digital health companies in Europe.Headquartered in Cambridge, we’re an international team with 12 nationalities and a unified passion for increasing efficiency for healthcare with human-centric technology. We exist to transform the way a nation delivers its healthcare to its population, all the way from prescriptions to personalised clinical services. | Venture - Series Unknown / Mar 01, 2021 | |
Oto Health
|
Oto builds digital therapeutics for tinnitus. There are 390 million people with intrusive tinnitus around the world. Our mission to help them, by providing science-based therapy, that is accessible to all. | Feb 23, 2021 | |
|
Oto Health
|
Oto builds digital therapeutics for tinnitus. There are 390 million people with intrusive tinnitus around the world. Our mission to help them, by providing science-based therapy, that is accessible to all. | $42.4K / Pre-Seed / Feb 23, 2021 | |
Skin Analytics
|
Skin Analytics build a digital history of your skin so that you and your doctor can measure, track and ultimately understand your skin. Meaning you have the tools to take control and ultimately improve your skin health.Their patent-pending algorithms measure how the skin is changing from smartphone images to identify, inform and evaluatetreatment options across a range of consumer health and clinical skin conditions.Which means they build digital platforms that personalise skin health so people can control their skin health rather than be controlled by it.They’re focused on delivering a series of skin health products over the next 3 years ranging from consumer to clinical. | $5.2M / Series A / Sep 08, 2020 | |
Knokcare
|
Knok is an app-based healthcare platform offering patients a holistic solution for their health through a combination of AI chatbots, video calls, face to face appointments at home, and integration with hospitals in one single application. This solution is convenient for the patient and efficient for the health system: the AI chatbot helps patientsself-assess their condition and directs the patient within the app to a video appointment or a face to face appointment. If the issue is serious enough, knock will direct the patient to the hospital. | Non-equity Assistance / Jul 02, 2020 | |
Log my Care
|
Log my Care is a care management system for social care providers. | Jul 02, 2020 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does RYSE Asset Management invest in?
RYSE Asset Management invests primarily in Health Care, Software and Medical startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 16 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact RYSE Asset Management?
Public channels for RYSE Asset Management include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RYSE Asset Management?
The team at RYSE Asset Management includes Shabir Chowdhary (Managing Partner), Vivien de Tusch-Lec (General Partner) and Chris Turner (Entrepreneur-in-Residence), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
